1-4 of 4
Daniella Zheleva, PhD
Close
Sort by
Journal Articles

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Hind Al Azzawi, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1379.
https://doi.org/10.1182/blood-2019-131348
Published: 2019
Journal Articles

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, MD PhD, Seung Tae Lee, MD PhD, Rong Chen, PhD, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD, William Plunkett, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1761.
https://doi.org/10.1182/blood-2019-128956
Published: 2019
Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3926.
https://doi.org/10.1182/blood-2019-131930
Published: 2019
Journal Articles

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Wittawat Chantkran, MD MSc, Daniella Zheleva, PhD, Sheelagh Frame, PhD, Ya-Ching Hsieh, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 3938.
https://doi.org/10.1182/blood-2019-124072
Published: 2019